Richter S, Shalev M, Nissenkorn I
Dept. of Urology, Sapir Medical Center, Kfar Saba and Sackler School of Medicine, Tel Aviv University.
Harefuah. 1990 Aug;119(3-4):66-7.
Vasoactive intracavernous pharmacotherapy (VIP) has become an important tool for the treatment of erectile impotence. The average age of patients treated has been only 59 years and the oldest, 79. We describe the results of VIP in the oldest group of patients described. 28 men, 65-84 years old (average 70), were treated for organic impotence with intracavernous injections of a mixture containing 25 mg/ml papaverine HCl and 0.83 mg/ml phentolamine. Treatment was started with an injection of 0.25 ml of the mixture, with increments of 0.25 ml until there was functional erection, or untip a total of 1.5 ml was injected. Full erection was obtained in 46.5%, while in 40.0% there was a mild nonfunctional erection and in 13.4% no reaction to treatment. The response to the injection was similar in the different etiologic groups. There were no complications, such as prolonged erections or adverse reactions to the drugs injected. We conclude that elderly men seek help in order to have normal sexual function. We therefore think that VIP has a definite place in the treatment of impotence of the elderly.
海绵体内血管活性药物治疗（VIP）已成为治疗勃起功能障碍的重要手段。接受治疗患者的平均年龄仅为59岁，年龄最大的为79岁。我们描述了在已报道的最年长患者组中VIP治疗的结果。28名年龄在65至84岁（平均70岁）的男性因器质性阳痿接受了海绵体内注射含25mg/ml盐酸罂粟碱和0.83mg/ml酚妥拉明混合物的治疗。治疗从注射0.25ml混合物开始，每次增加0.25ml，直至出现功能性勃起，或直至总共注射1.5ml。46.5%的患者获得了完全勃起，40.0%的患者出现轻度无功能勃起，13.4%的患者对治疗无反应。不同病因组对注射的反应相似。未出现诸如持续性勃起或对注射药物的不良反应等并发症。我们得出结论，老年男性为了获得正常性功能而寻求帮助。因此，我们认为VIP在老年阳痿的治疗中具有明确的地位。
